AlphAIAlphAI — Financial news for AI agents
scanx.tradeOCT 22 min read

Integra LifeSciences shares drop 17% on revenue miss and probe

Integra LifeSciences (IART) shares dropped 17% after missing Q3 revenue estimates ($410M-$412M vs. $416.3M) and lowering FY26 guidance due to flood damage. The company faces a probe over potential misleading statements. Q4 revenue may be further impacted by $15M-$20M. Insurance is expected to mitigate some losses.

Original reporting
scanx.trade
Published Oct 2, 2026, 10:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 4, 2026, 8:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Integra LifeSciences shares drop 17% on revenue miss and probe — source image
Source · scanx.trade
Decision brief

The 30-second read

High
01

Why it matters

The combination of a revenue miss, lowered guidance, and legal scrutiny creates immediate downside risk, but insurance recoveries and cash flow strength may cushion long‑term performance.

02

Market read

The news directly impacts IGL's stock price and may influence sentiment toward other med‑tech companies with similar supply‑chain risks.

03

What to watch

Potential upside from cost‑cutting measures and strong cash flow generation not fully reflected in the price decline.

Relevance 8/10Novelty 8/10Timing: intraday today

Background

Integra LifeSciences disclosed a July flood at its Cincinnati plant that reduced Q3 revenue and prompted a $7M impact, leading to a guidance cut and a securities investigation.

Market effects

Sector

Medical technology sector may see broader risk reassessment for companies with flood‑related supply chain exposure.

Regional

U.S. healthcare stocks could face modest sell pressure.

Global

Limited to U.S. listed med‑tech firms; no immediate global macro effect.

Counterpoint

What could challenge this read

If insurance recoveries exceed expectations, the earnings impact could be muted, offering a buying opportunity on the dip.

Key entities

  • Executive
    Stuart Essig

    Chairman and CEO of Integra LifeSciences, discussed recovery plans.

  • Legal Firm
    SueWallSt

    Notified investors of a pending securities investigation.

Read at source← All news

Also covered by

6 outlets

Related articles

OCT 2
$IARTHighAI 8/10

Why Integra LifeSciences (IART) Stock Is Nosediving

Integra LifeSciences (IART) shares dropped 15.3% after reducing full-year revenue and EPS guidance due to flood-related operational disruptions. The company expects Q3 operating cash flow above $85M and full-year cash flow between $190M-$200M. The stock has high volatility, with a 23% drop last year on weak guidance.

finance.yahoo.com2 min
OCT 2
$IARTHighAI 8/10

Why is Integra LifeSciences stock tumbling today?

Integra LifeSciences (IART) shares fell 16.2% to $13.49 after lowering its 2026 revenue and EPS guidance due to flooding damage at a key facility. The company expects $7M in Q3 revenue loss and $15M-$20M in Q4. It also announced a $600M debt refinancing. The stock dropped despite a positive U.S. market day.

investing.com2 min